BPC-157 and TB-500 for BBL recovery: What the science says

What did @hey_munchy actually say?

The creator is on a quest to find a peptide-based alternative to surgical BBL (Brazilian Butt Lift), testing whether localized peptide injections can grow glute muscles specifically. They reviewed four compounds: IGF-1 DES, MGF, ACE-083, and FST-288, framing the first two as "muscle growth peppers" and the last two as "myostatin blockers." They also claimed creatine only adds water, not real muscle tissue, as a contrast point.

The creator deserves credit for actually researching half-lives, trial phases, and cancer contraindications before recommending anything. That's more due diligence than most TikTok peptide content shows. But several specific claims need examination, and the broader premise of injecting unregulated research compounds into your glutes for cosmetic muscle growth carries risks that didn't get enough airtime here.

Does the science back this up?

Partially, but the animal-to-human translation is being treated as far more reliable than it actually is. The 48% mass increase figure for IGF-1 DES comes from rodent studies, and rodent IGF-1 signaling does not map cleanly onto human muscle physiology. The creator acknowledges no human trials exist, which is accurate, but then proceeds to give dosing context anyway.

For MGF (Mechano Growth Factor), the two-to-five minute half-life claim is broadly consistent with literature on the unmodified peptide. Coleman et al. (2006, Journal of Applied Physiology) confirmed MGF splice variant expression follows mechanical loading, but in vitro and rodent data dominate the field. ACE-083 reaching Phase 2 trials is accurate. Acceleron Pharma conducted trials in facioscapulohumeral muscular dystrophy and Charcot-Marie-Tooth disease. The 16% local muscle volume increase in treated legs was real, per Bettis et al. (2020, Muscle and Nerve), but the trials were discontinued in 2019 after the drug failed to improve functional strength outcomes. FST-288 (follistatin 288) data is almost entirely preclinical.

What did they get wrong (or right)?

The creatine claim is wrong and it matters. The creator says "the moment you start taking creatine then the water dissolves and you're back to square one." This misrepresents the evidence. Creatine supplementation does increase intramuscular water retention, but years of research including meta-analyses by Lanhers et al. (2017, European Journal of Sport Science) confirm creatine also supports genuine myofibrillar protein accretion over time, particularly with resistance training. Calling it purely cosmetic inflation is inaccurate.

The cancer contraindication warning for IGF-1 family peptides is genuinely correct and responsible. Growth factor signaling can accelerate proliferation in existing tumor cells. That warning belongs in any honest discussion of this compound class. The creator also correctly identifies that ACE-083 was discontinued due to lack of functional strength improvement, not safety failure, which is an important nuance most creators skip entirely.

Where the framing gets shaky is in treating "local inject" as a reliable containment mechanism. The assumption that these peptides stay in the injection site is not well-supported. Systemic IGF-1 elevation after local injection has been observed in animal models.

What should you actually know?

None of these compounds are approved by the FDA for cosmetic muscle enhancement. IGF-1 DES, MGF, and FST-288 are research chemicals with no established human dosing, no long-term safety data, and no regulatory oversight on purity or concentration when purchased from peptide vendors. The supply chain the creator is navigating, with vendors going in and out of stock tied to Chinese manufacturing schedules, is not a regulated pharmaceutical supply chain.

The hypoglycemia risk flagged for IGF-1 DES is real. IGF-1 receptor activation mimics insulin signaling and acute hypoglycemia has been documented even in controlled research settings. A banana nearby is not a clinical safety protocol.

If you are drawn to this content because you want a non-surgical body composition change, that goal is legitimate. But the compounds being discussed here sit at the outer edge of what any responsible clinician would supervise, and the gap between "impressive animal trial" and "safe for human cosmetic use" is not a technicality. It is the entire regulatory framework that exists to protect patients.